Add this topic to your myFT Digest for news straight to your inbox
Swiss group takes bold step to focus on faster-growing and higher-margin medicines
The Swiss company’s chief executive has to decide on the future of its $10bn generics business
Potential suitors include Blackstone and Carlyle but no formal bids have been made
Selling off its Sandoz unit could help stave off an attack by activists
Blackstone, Carlyle and EQT among those interested in bidding for drug manufacturer Sandoz
Unit accounts for a fifth of group sales and could be spun off
US watchdog bullish on copycat biotech drug that could help cut ballooning healthcare costs
International Edition